Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Eye Contact Lens ; 48(6): 272-275, 2022 Jun 01.
Article in English | MEDLINE | ID: mdl-35703836

ABSTRACT

PURPOSE: To report the clinical profile and treatment outcomes of patients with culture-positive Acremonium keratitis. METHODS: This is a retrospective observational study. Medical records of all patients treated in a tertiary eye hospital for culture positive infective keratitis from March 2016 to February 2021 were screened, of which those positive for Acremonium species on fungal culture were reviewed. Demographic details, clinical presentation, clinical course, treatment given, total follow-up duration, time taken for ulcer to heal, scar size, and final visual acuity in the last follow-up were recorded. RESULTS: Fifty three cases of fungal keratitis caused by Acremonium species were identified, 22 females and 31 males, with average age of 46.39±18.64 years. The mean duration of symptoms being 54.47±50 days. Only five patients had a history of trauma with vegetative matter. Clinical presentation of patients showed a large number of variations, with 2 patients presenting as peripheral ulcerative keratitis and 1 with epithelial plaque. The mean visual acuity of patients at presentation was 2.43±0.46 logMAR units. Thirty-three of 53 patients presented with perforated corneal ulcer and underwent penetrating keratoplasty; 20 patients were medically managed on topical voriconazole 1%, natamycin 5%, and oral voriconazole. The mean duration of healing of epithelial defect was 95±60.62 days (range 60-165 days). CONCLUSION: Acremonium keratitis has a long and indolent course. A prolonged combination therapy of natamycin and voriconazole seems to be effective in the management. A delay in the diagnosis of Acremonium keratitis often leads to clinical worsening requiring keratoplasty.


Subject(s)
Acremonium , Corneal Ulcer , Eye Infections, Fungal , Keratitis , Adult , Aged , Antifungal Agents/therapeutic use , Corneal Ulcer/diagnosis , Corneal Ulcer/drug therapy , Eye Infections, Fungal/diagnosis , Eye Infections, Fungal/drug therapy , Eye Infections, Fungal/microbiology , Female , Humans , Keratitis/diagnosis , Keratitis/drug therapy , Keratitis/microbiology , Male , Middle Aged , Natamycin/therapeutic use , Treatment Outcome , Voriconazole/therapeutic use
2.
Cornea ; 40(12): 1629-1632, 2021 Dec 01.
Article in English | MEDLINE | ID: mdl-34483273

ABSTRACT

PURPOSE: The purpose of this study was to report an unusual case of bilateral immune-mediated corneal melting and necrosis after ChAdOx1 nCoV-19 (Covishield) vaccination. METHODS: This is a case report and literature review. RESULTS: A 48-year-old man presented to the ophthalmic emergency department with progressive bilateral corneal melting 5 weeks after receiving the first dose of ChAdOx1 nCoV-19 (Covishield) vaccine. Systemic complaints of fever, diarrhea, and vomiting were noted in the first 2 weeks, which subsided before the onset of ocular symptoms at day 21 of vaccine administration. The patient could only perceive light bilaterally and demonstrated features of bilateral keratolysis with choroidal detachment on ultrasonography. The microbiological scraping specimen did not reveal growth of any microorganism. Tectonic penetrating keratoplasty was performed, and the host corneal tissue was sent for histopathology, bacterial culture, fungal culture, polymerase chain reaction for herpes simplex virus, varicella zoster virus, cytomegalovirus, adenovirus, and SARS-CoV-2. Microbial culture was sterile, and viral polymerase chain reaction reports were negative. Histopathological examination revealed dense inflammatory cell infiltration. Detailed systemic workup revealed no underlying systemic or autoimmune pathology. CONCLUSIONS: Immune-mediated keratolysis after ChAdOx1 nCoV-19 (Covishield) vaccination is a rare entity, and we believe that this is the first report of a temporal association between a serious ocular adverse event after a single dose of any SARS-CoV-19 vaccine. It may be included as a possible adverse event associated with this vaccine.


Subject(s)
COVID-19 Vaccines/adverse effects , COVID-19/immunology , Cornea/pathology , Corneal Diseases/etiology , Drug-Related Side Effects and Adverse Reactions/immunology , Immunization/adverse effects , SARS-CoV-2/immunology , ChAdOx1 nCoV-19 , Corneal Diseases/surgery , Humans , Immunogenicity, Vaccine , Keratoplasty, Penetrating , Male , Middle Aged , Necrosis , Vaccination/adverse effects
3.
Cornea ; 37(12): 1590-1592, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30234681

ABSTRACT

PURPOSE: To report an unusual case of isolated Acremonium eumycetoma presenting as a protuberant mass over the cornea. METHODS: Case report and literature review. RESULTS: A 55-year-old male patient referred to our center with a case of perforated corneal ulcer with uveal tissue prolapse was examined in the casualty department and found to have central melt, approximately 8 mm, along with suspected uveal tissue prolapse. A provisional diagnosis of sloughed corneal ulcer with uveal prolapse was made along with differential diagnoses of fungal ball and infected foreign body granuloma. Tectonic penetrating keratoplasty under general anesthesia was planned. Intraoperatively, the suspected uveal (brown colored) tissue was found to be an epicorneal mass growing over an intact and infiltrated cornea. Histopathological and microbiological analysis of the epicorneal mass and host cornea revealed it to be a fungal ball (mass full of septate hyphae) with growth of Acremonium species on culture. The patient was administered topical and oral antifungal agents postoperatively, in addition to topical antibiotics and cycloplegics. CONCLUSIONS: Isolated corneal Acremonium eumycetoma masquerading as a perforated corneal ulcer with prolapsed uveal tissue is a rare entity. Surgical intervention and appropriate antimicrobial therapy are key to successful outcome.


Subject(s)
Acremonium/isolation & purification , Cornea/microbiology , Eye Infections, Fungal/microbiology , Keratitis/microbiology , Mycetoma/microbiology , Antifungal Agents/therapeutic use , Cornea/pathology , Eye Infections, Fungal/diagnosis , Humans , Keratitis/diagnosis , Keratitis/therapy , Keratoplasty, Penetrating , Male , Middle Aged , Mycetoma/diagnosis , Mycetoma/therapy
4.
J Cancer Res Ther ; 11(3): 646, 2015.
Article in English | MEDLINE | ID: mdl-26458603

ABSTRACT

Cedecea lapagei is a member of the family Enterobacteriaceae and is an uncommon pathogen. There are very few reports of isolation of this organism from biological samples; mostly it is found to be a pathogen in elderly or otherwise medically compromised. We present a rare case of a patient with underlying malignancy of buccal mucosa, who developed an oral ulcer superinfected with C. lapagei. According to the available literature, this is the first case of C. lapagei from India detected in a cancer patient.


Subject(s)
Carcinoma, Squamous Cell/diagnostic imaging , Enterobacteriaceae Infections/diagnosis , Mouth Neoplasms/diagnostic imaging , Ulcer/diagnosis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/therapy , Chemoradiotherapy , Cisplatin/administration & dosage , Cycloserine/administration & dosage , Humans , Male , Middle Aged , Mouth Neoplasms/therapy , Radiography , Ulcer/microbiology , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...